Clinical Trial Search

Primary: Percent Change From Baseline in Total Sign Score (TSS) at Week 6: In-person Assessment — -18.07; -32.44 Percent change — p=0.0299

Primary: Dietary Quality Change — 57.01 Change in HEI-2015 baseline to 12 weeks — p=<0.05

Primary: Total Opioid Use — 22.5; 30.0 mg (morphine equivalent)

Primary: Percentage of Subjects Who Achieve Pain Relief — 3; 5; 5 Participants

Primary: Time to Lapse on a Smoking Lapse Analogue Task — 16.11; 38.0; 26.36; 15.25 minutes

Primary: Evaluate the Navio™ System for Revisions at 2+ Years Post-surgical Implantation Survivorship — 0; 0; 1; 0 participants

Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Day 29 — -42.79; -59.92 Percent Change — p=0.0002

Primary: Plasma Supernatant Hemoglobin — 26.8; 28.0 mg/dL

Primary: Maximum Tolerated Dose (MTD) of Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) — 2 mcg/kg/dose

Primary: Percent Change From Baseline in Partial-onset Seizure Frequency Per 28 Days — -24.0; -35.5; -55.0; -55.0 percent change — p=<0.001

Primary: Least Squares Mean Dyskinesia Severity Area Under the Curve (AUC) Score As Assessed By Modified Movement Disorder Society-Unified Dyskinesia Rating Scale (MDS-UDysRS)…

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each H1ssF_3928 Product Administration — 5; 8; 11; 9 Participants

Primary: Proportion of Subjects Who Discontinue Study Drug Due to Adverse Events — 1; 0 Participants

Primary: Total Fertilization Proportion (i.e. Total Competent Proportion) — 0.59; 0.65 ratio

Primary: Number of Participants With Adverse Events — 0 Participants